Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 209

The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.

Metformin Inhibits Growth of Human Glioblastoma Cells and Enhances Therapeutic Response

Open access
Sesen, Julie, Dahan, Perrine, Scotland, Sarah J., Saland, Estelle, Dang, Van-Thi, Lemarié, Anthony, Tyler, Betty M., Brem, Henry, Toulas, Christine, Cohen-Jonathan Moyal, Elizabeth, Sarry, Jean-Emmanuel, Skuli, Nicolas·2015·PLOS ONE

Abstract

High-grade gliomas, glioblastomas (GB), are refractory to conventional treatment combining surgery, chemotherapy, mainly temozolomide, and radiotherapy. This highlights an urgent need to develop novel therapies and increase the efficacy of radio/chemotherapy for these very aggressive and malignant brain tumors. Recently, tumor metabolism became an interesting potential therapeutic target in various cancers. Accordingly, combining drugs targeting cell metabolism with appropriate chemotherapeutic agents or radiotherapy has become attractive. In light of these perspectives, we were particularly interested in the anti-cancer properties of a biguanide molecule used for type 2 diabetes treatment, metformin. In our present work, we demonstrate that metformin decreases mitochondrial-dependent ATP production and oxygen consumption and increases lactate and glycolytic ATP production. We show that metformin induces decreased proliferation, cell cycle arrest, autophagy, apoptosis and cell death in vitro with a concomitant activation of AMPK, Redd1 and inhibition of the mTOR pathway. Cell sensitivity to metformin also depends on the genetic and mutational backgrounds of the different GB cells used in this study, particularly their PTEN status. Interestingly, knockdown of AMPK and Redd1 with siRNA partially, but incompletely, abrogates the induction of apoptosis by metformin suggesting both AMPK/Redd1-dependent and -independent effects. However, the primary determinant of the effect of metformin on cell growth is the genetic and mutational backgrounds of the glioma cells. We further demonstrate that metformin treatment in combination with temozolomide and/or irradiation induces a synergistic anti-tumoral response in glioma cell lines. Xenografts performed in nude mice demonstrate in vivo that metformin delays tumor growth. As current treatments for GB commonly fail to cure, the need for more effective therapeutic options is overwhelming. Based on these results, metformin could represent a potential enhancer of the cytotoxic effects of temozolomide and/or radiotherapy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pone.0123721

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 12 references

Cited by

See all 209

Metadata

Authors
Sesen, J., Dahan, P., Scotland, S. J., Saland, E., Dang, V.-T., Lemarié, A., Tyler, B. M., Brem, H., Toulas, C., Cohen-Jonathan Moyal, E., Sarry, J.-E., & Skuli, N.
Venue
PLOS ONE
Published
2015-04-13
Volume
10
Issue
4
Pages
e0123721
ISSN
1932-6203 (ISSN-L)
OpenAlex
W1976993918
Cited by
209
References
12
FWCI
7.98
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Metformin Inhibits Growth of Human Glioblastoma Cells and Enhances Therapeutic Response. https://app.cochat.ai/papers/10.1371/journal.pone.0123721
The paper
Sesen, J., Dahan, P., Scotland, S. J., Saland, E., Dang, V.-T., Lemarié, A., Tyler, B. M., Brem, H., Toulas, C., Cohen-Jonathan Moyal, E., Sarry, J.-E., & Skuli, N. (2015). Metformin Inhibits Growth of Human Glioblastoma Cells and Enhances Therapeutic Response. PLOS ONE. https://doi.org/10.1371/journal.pone.0123721

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.